文献速递创伤与烧伤心脑血管急症

服用新型口服抗凝药的创伤患者无需重复头颅CT:一项多中心研究

Repeat computed tomography head scan is not indicated in trauma patients taking novel anticoagulation: A multicenter study.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论服用NOAC的创伤患者初次头颅CT阴性后迟发性颅内出血发生率低(2.3%),且无需神经外科干预或死于颅脑损伤,重复头颅CT似乎不必要。

这项多中心回顾性研究纳入2016至2018年北加州5家一级创伤中心的777例抗凝创伤患者(NOAC 346例,华法林431例),初次头颅CT均为阴性。NOAC组迟发性颅内出血发生率为2.3%,华法林组为4%(p=0.31)。NOAC组发生迟发性颅内出血的患者均无需神经外科干预,也无死于颅脑损伤者;华法林组有2例接受神经外科干预、3例死于颅脑损伤。作者结论认为该人群重复头颅CT似乎不必要。

要点

  • 服用NOAC的创伤患者初次头颅CT阴性后,迟发性颅内出血发生率为2.3%,华法林组为4%,两组差异无统计学意义(p=0.31)。
  • NOAC组发生迟发性颅内出血的患者均未接受神经外科干预,也无死于颅脑损伤者。
  • 华法林组有2例接受神经外科干预、3例死于颅脑损伤。
  • 头部简明损伤定级≥3分与迟发性颅内出血风险增加相关(校正OR 32.70,p<0.01)。
  • 作者认为该人群重复头颅CT似乎不必要。

适用人群与场景

  • 院前服用新型口服抗凝药或华法林的创伤患者,且初次头颅CT结果为阴性。

诊断标准与关键阈值

  • 头部简明损伤定级≥3分与迟发性颅内出血风险增加相关(校正OR 32.70,p<0.01)。

研究设计与关键结果

  • 研究类型:回顾性综述,北加州5家一级创伤中心参与,纳入2016至2018年777例抗凝创伤患者(NOAC组346例,华法林组431例),54%接受了重复头颅CT。
  • 主要结局:迟发性颅内出血发生率NOAC组2.3% vs 华法林组4%(p=0.31)。
  • 神经外科干预与死亡:NOAC组发生迟发性颅内出血者均无需神经外科干预,也无死于颅脑损伤者;华法林组2例接受神经外科干预、3例死于颅脑损伤。
  • 头部简明损伤定级≥3分与迟发性颅内出血风险增加相关(校正OR 32.70,p<0.01)。

证据类型、等级与局限

  • 证据类型:预后/流行病学研究,证据等级III;治疗性证据等级IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,服用NOAC的创伤患者初次头颅CT阴性后,重复头颅CT似乎不必要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The number of trauma patients on prehospital novel oral anticoagulants (NOACs) is increasing. After an initial negative computed tomography of the head (CTH), practice patterns are variable for obtaining repeat CTH to evaluate for delayed intracranial hemorrhage (ICH-d). However, the risks and outcomes of ICH-d for patients on NOACs are unclear. We hypothesized that, for these patients, the incidence of ICH-d is low, similar to that of warfarin, and when it occurs, it does not result in clinically significant worse outcomes.

METHODS: Five level 1 trauma centers in Northern California participated in a retrospective review of anticoagulated trauma patients. Patients were included if their initial CTH was negative. Primary outcomes were incidence of ICH-d, neurosurgical intervention, and death. Patient factors associated with the outcome of ICH-d were determined by multivariable regression.

RESULTS: From 2016 to 2018, 777 patients met the inclusion criteria (NOAC, n = 346; warfarin, n = 431), 54% of whom received a repeat CTH. Delayed intracranial hemorrhage incidence was 2.3% in the NOAC group and 4% in the warfarin group (p = 0.31). No NOAC patient with ICH-d required neurosurgical intervention or died because of their head injury. Two warfarin patients received neurosurgical intervention, and three died from their head injury. Head Abbreviated Injury Scale ≥3 was associated with increased odds of developing ICH-d (adjusted odds ratio, 32.70; p < 0.01).

CONCLUSION: The incidence of ICH-d in patients taking NOAC is low. In this study, patients on NOACs who developed ICH-d after an initial negative CTH did not need neurosurgical intervention or die from their head injury. Repeat CTH in this patient population does not appear necessary.

LEVEL OF EVIDENCE: Prognostic/epidemiologic study, level III.Therapeutic, level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Cohan CM, Beattie G, Bowman JA, et al. Repeat computed tomography head scan is not indicated in trauma patients taking novel anticoagulation: A multicenter study. J Trauma Acute Care Surg. 2020. PMID: 32332255. doi:10.1097/TA.0000000000002760

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。